Clinical milestones keep shifting, but your financial model still reflects the original plan.
You're managing grants, equity, and subsidies at once, with no unified view of your runway.
Regulatory delays are burning cash you hadn't budgeted for.
Your investor reporting reads like a science update, not a financial case.
Your finance setup was built for a pre-clinical team. It won't carry you through commercialization.
